Exact Sciences is in a Downtrend, With No End in Sight
Shares of Exact Sciences (EXAS) have been in a long-term downtrend, and with no profits, the stock could go lower.
Shares of Exact Sciences (EXAS) have been in a long-term downtrend, and with no profits, the stock could go lower.
Exact Sciences (EXAS) stock has been in a big downtrend, but the shares could rise if cancer screening becomes pupular.
Exat Sciences (EXAS) has a one-two punch against cancer in its Cologuard and Oncotype DX tests. But the stock is in neutral.
Exact Sciences (EXAS), maker of the Cologuard colon cancer test, now has its eyes on multi-cancer screening.
Exact Sciences (EXAS) is making new highs after showing promising results for its breast cancer test.